Claims for Patent: 8,673,341

Summary for Patent: 8,673,341

Title:	Intraocular pressure reduction with intracameral bimatoprost implants
Abstract:	The present invention provides a method of treating an ocular condition in an eye of a patient, comprising the step of placing a biodegradable intraocular implant in an eye of the patient, the implant comprising a prostamide and a biodegradable polymer matrix that releases drug at a rate effective to sustain release of an amount of the prostamide from the implant to provide an amount of the prostamide effective to prevent or reduce a symptom of an ocular condition of the eye, wherein said ocular condition is elevated IOP and said implant is placed in an intracameral location to dilate the outflow channels of the eye emanating from Schlemm's Canal.
Inventor(s):	Hughes; Patrick M. (Aliso Viejo, CA)
Assignee:	Allergan, Inc. (Irvine, CA)
Application Number:	12/761,765
Patent Claims:	1. A method of treating an ocular condition, comprising the step of placing a biodegradable intraocular implant in an eye of the patient in need of said treatment, said implant comprising a therapeutic component associated with a biodegradable polymer matrix that releases an amount of the therapeutic component effective to reduce a symptom of the ocular condition of the eye, wherein said ocular condition is elevated intraocular pressure (IOP), wherein the therapeutic component consists of a postamide, and wherein said implant is placed in the anterior chamber of the eye. 2. The method of claim 1 wherein said prostamide is a compound having the formula (I) ##STR00005## wherein the dashed bonds represent a single or double bond which can be in the cis or trans configuration, A is an alkylene or alkenylene radical having from two to six carbon atoms, which radical may be interrupted by one or more oxide radicals and substituted with one or more hydroxy, oxo, alkyloxy or akylcarboxy groups wherein said alkyl radical comprises from one to six carbon atoms; B is a cycloalkyl radical having from three to seven carbon atoms, or an aryl radical, selected from the group consisting of hydrocarbyl aryl and heteroaryl radicals having from four to ten carbon atoms wherein the heteroatom is selected from the group consisting of nitrogen, oxygen and sulfur atoms; X is --N(R.sup.4).sub.2 wherein R.sup.4 is independently selected from the group consisting of hydrogen and a lower alkyl radical having from one to six carbon atoms; Z is .dbd.O; one of R.sub.1 and R.sub.2 is .dbd.O, --OH or a --O(CO)R.sub.6 group, and the other one is --OH or --O(CO)R.sub.6, or R.sub.1 is .dbd.O and R.sub.2 is H; wherein R.sub.6 is a saturated or unsaturated acyclic hydrocarbon group having from 1 to about 20 carbon atoms, or --(CH.sub.2)mR.sub.7 wherein m is 0-10, and R.sub.7 is cycloalkyl radical, having from three to seven carbon atoms, or a hydrocarbyl aryl or heteroaryl radical, as defined above. 3. The method of claim 2 wherein the prostamide has the following formula (II) ##STR00006## wherein y is 0 or 1, x is 0 or 1 and x+y are not both 1, Y is a radical selected from the group consisting of alkyl, halo, nitro, amino, thiol, hydroxy, alkyloxy, alkylcarboxy and halo substituted alkyl, wherein said alkyl radical comprises from one to six carbon atoms, n is 0 or an integer of from 1 to 3 and R.sub.3 is .dbd.O, --OH or --O(CO)R.sub.6 and hatched lines indicate the a configuration and solid triangles indicate the .beta. configuration. 4. The method of claim 1, wherein the amount of prostamide is released into the eye for a period of time greater than about one week after the implant is placed in the eye. 5. The method of claim 1, wherein the prostamide is bimatoprost.